This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical: Archive
10x Genomics & Fred Hutch Join Forces on Cancer Biomarker Research
by Zacks Equity Research
TXG teams up with Fred Hutchinson Cancer Center to advance precision oncology through single-cell and spatial technologies targeting two cancer types.
TXGPositive Net Change MMSIPositive Net Change OPKNegative Net Change GMEDNegative Net Change
medical medical-devices
Here's Why You Should Retain WAT Stock in Your Portfolio for Now
by Zacks Equity Research
Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.
WATNegative Net Change WSTNegative Net Change OPKNegative Net Change GMEDNegative Net Change
medical medical-devices
5 Attractive Low Price-to-Sales Stocks With Promising Upside Potential
by Rajani Lohia
DINO, INVA, PARR, GNW and PBF stand out as low price-to-sales stocks with promising upside potential. Discover how attractive valuations can uncover hidden value.
GNWPositive Net Change PBFPositive Net Change INVANegative Net Change PARRPositive Net Change DINOPositive Net Change
finance insurance medical oil-energy pharmaceuticals
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
by Zacks Equity Research
RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.
RAREPositive Net Change ALNYPositive Net Change ALDXNegative Net Change CRSPNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bruker Gains 66.3% in a Year: What's Driving the Rally?
by Zacks Equity Research
BRKR shares surge 66.3% in a year, fueled by strong demand in mass spectrometry and biopharma, despite restructuring challenges and currency headwinds.
BRKRNegative Net Change TFXNegative Net Change OPKNegative Net Change VCYTPositive Net Change
medical
Moderna's Nasdaq-100 Entry: What Does It Mean for the Stock?
by Sundeep Ganoria
MRNA's Nasdaq-100 entry follows a 566% stock surge and stronger cancer therapy prospects, potentially boosting demand from index-tracking funds.
MRNAPositive Net Change MRKNegative Net Change SKYDPositive Net Change
biotechs internet medical multi-sector-conglomerates pharmaceuticals vaccines
How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings?
by Ahan Chakraborty
LLY's oncology portfolio is poised for growth as Jaypirca, Inluriyo and Retevmo may offset slower Verzenio sales and mature-drug declines.
LLYNegative Net Change AZNNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Company News for Oct 8, 2026
by Zacks Equity Research
Companies In The Article are:STZ,PENG,SPCX,MRNA
MRNAPositive Net Change STZPositive Net Change SPCXNegative Net Change PENGNegative Net Change
artificial-intelligence consumer-staples medical
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now
by Zacks Equity Research
FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.
FMSPositive Net Change MMSIPositive Net Change WSTNegative Net Change GMEDNegative Net Change
medical medical-devices
Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?
by Indrajit Bandyopadhyay
Intuitive Surgical SP platform is gaining momentum as procedures, utilization and placements rise, with expanding indications and global adoption fueling growth.
ISRGPositive Net Change EWNegative Net Change GKOSNegative Net Change
medical medical-devices